ABBV
AbbVie Inc
262.80$
+1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.1% | +10.5% | -4.7% | +1.0% | -5.8% | +0.7% | +0.7% | -2.4% | +0.0% | +1.9% | -1.0% | |
| – | -0.7% | +17.8% | -13.0% | -17.8% | -7.9% | +8.2% | +5.7% | -2.5% | +1.8% | +15.4% | +0.4% | |
| – | -3.6% | +41.0% | -27.3% | -44.7% | -23.9% | -6.3% | +25.0% | -13.0% | -7.1% | +79.6% | -30.1% | |
| – | -3.6% | +41.0% | -27.2% | -44.6% | -23.7% | -6.8% | +24.9% | -12.3% | -7.3% | +78.6% | -30.1% | |
| – | -2.3% | +7.1% | -1.9% | -2.1% | -4.8% | +14.3% | +1.3% | +1.0% | -1.4% | -0.9% | +10.8% | |
| – | +3.0% | +3.6% | -0.6% | +5.5% | -6.0% | +8.3% | +9.6% | -0.4% | +0.3% | +2.0% | +1.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.6% | +3.5% | -0.1% | +5.7% | -1.0% | +0.9% | +1.0% | 0.0% | +0.0% | -0.2% | -0.1% | |
| – | -5.1% | +11.9% | -3.2% | +10.6% | -9.9% | -2.6% | -2.5% | -4.8% | -3.1% | -3.4% | -3.4% | |
| – | +0.2% | +13.3% | -4.1% | +1.7% | -4.0% | +2.2% | +1.9% | -0.6% | +0.5% | +4.3% | -1.4% | |
| – | +8.8% | +9.7% | +0.9% | +2.7% | -10.0% | -6.1% | +9.2% | -0.9% | +9.9% | -2.7% | -1.1% | |
| – | +40.6% | +41.8% | +23.4% | -0.1% | -45.9% | -21.2% | +40.3% | -23.3% | +48.2% | -2.7% | +0.2% | |
| – | -87.5% | +747.6% | -6.3% | +3.8% | +5.0% | -3.0% | +2.8% | +4.8% | +3.2% | -2.4% | -1.3% | |
| – | -6.2% | +22.2% | -9.0% | +0.8% | +3.1% | +6.9% | -2.4% | +0.0% | -6.4% | +9.5% | -3.2% | |
| – | -14.3% | -22.6% | -15.2% | -11.0% | -44.6% | -56.5% | -109.4% | – | – | – | – | |
| – | -207.2% | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.1% | -0.1% | +0.1% | +0.1% | -0.1% | +0.0% | +0.0% | +0.1% | +0.0% | -0.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.